Download presentation
Presentation is loading. Please wait.
Published byKelebek Akdemir Modified over 5 years ago
1
Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis
Anja Gunda Jung, MD, Hans-Peter Horny, MD, Karl Sotlar, MD, Tobias Overbeck, MD, Michael Peter Schön, MD, Undine Lippert, MD Journal of the American Academy of Dermatology Volume 65, Issue 1, Pages (July 2011) DOI: /j.jaad Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions
2
Fig 1 A, Reddish papules on the chest before treatment (overall involvement: 15% of the body surface with a 20% density). B, Reddish papules on the chest after 14 months of treatment with imatinib mesylate (overall involvement: 15% of the body surface with a 10% density). The extent of surface involvement was assessed as in burns. The density was calculated in the most affected area as percent lesional skin surface to total skin surface. Journal of the American Academy of Dermatology , DOI: ( /j.jaad ) Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions
3
Fig 2 Radiographic scan of the left humerus showing nonhomogeneously distributed multiple areas of osteolysis emphasized in the proximal and distal third of the humerus. Arrows show osteolysis. Journal of the American Academy of Dermatology , DOI: ( /j.jaad ) Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.